Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response

In a recent phase I clinical trial, a vaccine consisting of glypican-3 (GPC3)-derived CTL epitopes was found to be safe and induced measurable immune and clinical responses in patients with hepatocellular carcinoma (HCC). The aim of this study was to identify GPC3-derived long peptides (GPC3-LPs) ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayem, Mohammad A., Tomita, Yusuke, Yuno, Akira, Hirayama, Masatoshi, Irie, Atsushi, Tsukamoto, Hirotake, Senju, Satoru, Yuba, Eiji, Yoshikawa, Toshiaki, Kono, Kenji, Nakatsura, Tetsuya, Nishimura, Yasuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760284/
https://www.ncbi.nlm.nih.gov/pubmed/26942076
http://dx.doi.org/10.1080/2162402X.2015.1062209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760284/
https://www.ncbi.nlm.nih.gov/pubmed/26942076
http://dx.doi.org/10.1080/2162402X.2015.1062209

Ejemplares similares